Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)
ID: 337926Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/337926

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-097.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)" aimed at supporting innovative research on brain and nervous system disorders relevant to low- and middle-income countries (LMICs). This initiative encourages collaborative projects between U.S. and LMIC scientists, focusing on a range of neurological, mental, and behavioral disorders, and aims to enhance research capacity in resource-constrained environments. Eligible applicants include various institutions such as higher education entities, nonprofits, and government agencies from both the U.S. and LMICs, with an emphasis on interdisciplinary approaches that consider socio-economic factors. The application deadline is December 9, 2024, and interested parties can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. More details can be found in the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-097.html.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-097-Full-Announcement.html
    PAR-22-097.html
    The Department of Health and Human Services is issuing a Funding Opportunity Announcement (FOA) to support innovative research on brain and nervous system disorders relevant to Low and Middle-Income Countries (LMICs). This initiative, through the National Institutes of Health (NIH), aims to foster collaborative projects that enhance neuro-health research capacity and address the burden of neurological disorders across the lifespan. It encourages applications from both U.S. and LMIC institutions, emphasizing the need for studies on neurological, neurodevelopmental, and neuropsychiatric conditions. Eligible entities include higher education institutions, nonprofits, and government agencies from LMICs and the U.S., with a focus on building sustainable research infrastructure. The application process allows various project types, including those involving clinical trials. A significant emphasis is placed on interdisciplinary approaches that incorporate socio-economic factors and local contexts to improve treatment and intervention strategies. Key deadlines for application submission are specified, alongside guidelines for budgeting, eligibility, and required formats. The FOA encourages applicants to engage in preliminary collaborations and consultations to ensure relevance to the research priorities of participating NIH Institutes. This funding opportunity reflects a commitment to global health advancement by establishing necessary research frameworks in resource-constrained environments.
    Similar Opportunities
    Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)" aimed at supporting innovative research in the identification and development of novel compounds for the prevention and treatment of nervous system disorders. This initiative encourages applications focused on early-stage research, particularly in the areas of small molecules, biotechnology products, and biologics, with an emphasis on projects that utilize machine learning and propose preclinical evaluations of candidate drugs. The funding amount available is up to $275,000, with a submission deadline of January 7, 2025. Interested applicants can find more information and submission guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)," aimed at advancing research in human cell-derived microphysiological systems (MPS) that replicate complex nervous system architectures and functions. This initiative seeks innovative applications that address technological barriers in studying nervous system development and diseases, with a focus on improving physiological relevance and circuit-level activity in existing assays. The funding is open to a wide range of eligible applicants, including higher education institutions and non-profits, with a project period of up to five years and no cost-sharing requirement. Interested parties should note that the application deadline is January 7, 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the announcement page at https://grants.nih.gov/grants/guide/pa-files/PAR-23-046.html.
    Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R01 Research Project Grant aimed at advancing drug discovery for nervous system disorders. This initiative focuses on the identification, design, synthesis, and preclinical testing of novel therapeutic compounds, particularly emphasizing innovative approaches to drug metabolism and pharmacokinetics, while excluding clinical trial applications. The program encourages high-risk, novel projects that aim to translate scientific research into effective treatments for conditions such as mental illness and substance use disorders. Interested applicants can find more information and guidelines in the NIH Grant Application Guide, with applications due by January 7, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) to support innovative and exploratory research projects in neuroscience. This grant aims to facilitate early-stage studies that assess novel avenues of investigation, particularly those that may involve significant risk but hold the potential for breakthroughs in understanding neuroscience or developing new methodologies. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments, with funding available up to $200,000 over two years. Interested parties should submit their applications by January 7, 2025, and can find additional information and application guidelines at the NIH website or contact grantsinfo@nih.gov for assistance.
    Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research on the biological mechanisms underlying complex brain disorders such as schizophrenia, bipolar disorder, and autism. This initiative encourages studies that explore high-confidence risk factors associated with these disorders, focusing on intracellular, transcellular, and circuit mechanisms, while emphasizing the importance of disseminating findings to enhance data resources and therapeutic target identification. Eligible applicants include a wide range of institutions, including historically black colleges, tribal colleges, and various nonprofit organizations, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and detailed information can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-024.html.
    Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research on high-confidence risk factors associated with complex brain disorders. This grant encourages studies that focus on the intracellular, transcellular, and circuit substrates of neural function, allowing for both hypothesis-generating and hypothesis-testing research designs, while discouraging attempts to model the disorders themselves. The initiative is crucial for enhancing understanding of the biological processes impacted by these disorders, ultimately facilitating therapeutic target identification and enriching data resources. Applications are due by September 7, 2026, with no budget cap, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Integrating Mental Health Care into Health Care Systems and Non-Health Settings in Low- and Middle-Income Countries (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Integrating Mental Health Care into Health Care Systems and Non-Health Settings in Low- and Middle-Income Countries (R01 Clinical Trial Optional)." This initiative aims to support implementation research that develops, optimizes, and tests innovative strategies for integrating mental health care into both healthcare systems and community settings in low- and middle-income countries (LMICs). The focus is on enhancing accessibility, quality, and sustainability of mental health services while fostering partnerships between institutions in LMICs and high-income countries. Interested applicants can find more information and guidelines at the NIH grants website, with applications due by January 7, 2028. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for clinical studies aimed at advancing next-generation devices for recording and modulation in the human central nervous system, under the BRAIN Initiative. This initiative seeks to support small clinical trials that provide critical data necessary for the development of devices intended to treat central nervous system disorders, particularly those requiring an Investigational Device Exemption (IDE) from the FDA. The funding is crucial for enhancing neurotechnology and improving treatment outcomes, with NIH planning to allocate approximately $10 million annually for 5 to 7 awards, each with a maximum budget of $1.5 million per year for up to five years. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by September 28, 2026.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) aimed at advancing research in the development of next-generation human cell-derived microphysiological systems (MPS) that accurately replicate complex nervous system physiology. This funding opportunity, under the R01 Research Project Grant mechanism, encourages innovative applications that focus on enhancing existing technologies and creating sophisticated models for studying the nervous system's development, function, and aging, while explicitly excluding clinical trial projects. Eligible applicants include a diverse range of organizations, such as educational institutions and community-based organizations, with no specific budget limits as long as costs align with the proposed research. Interested parties should note that the application submission period opens on January 3, 2025, with a closing date of January 7, 2026, and are encouraged to contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.